Skip to main content
Smart Investors Daily
Codexis, Inc. logo

NASDAQ · CDXS

Codexis, Inc.

Healthcare · Biotechnology

$1.16

Down-$0.10 (-8.62%)

Updated Nov 17, 2026, 1:13 AM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
144.21M
P/E ratio
-2.4
Dividend yield
0.00%
52-week range
$0.90 – $2.98
Volume
2.5M
Avg. volume
910.65K

Price performance · CDXS

CDXS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

CDXS closed at $1.16 after 20 trading sessions, down 12.12% for the selected period.

Last close
$1.16
Period change
-12.12%
Period low
$0.96
Period high
$1.32
Daily close
View OHLC price history
CDXS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$1.13$1.20$1.035$1.162.5M
Nov 12, 2026$0.96$0.9686$0.90$0.95811.02M
Nov 11, 2026$1.00$1.015$0.95$0.97641.67M
Nov 10, 2026$1.12$1.145$1.00$1.00635.26K
Nov 9, 2026$1.11$1.1699$1.08$1.11792.97K
Nov 6, 2026$1.03$1.10$1.025$1.08400.32K
Nov 5, 2026$1.09$1.10$0.9904$1.02871.75K
Nov 4, 2026$1.11$1.13$1.065$1.08658.2K
Nov 3, 2026$1.04$1.08$1.04$1.08613.17K
Nov 2, 2026$1.20$1.22$1.04$1.0451.13M
Oct 30, 2026$1.20$1.24$1.17$1.19789.47K
Oct 29, 2026$1.27$1.296$1.20$1.22917.3K
Oct 28, 2026$1.28$1.33$1.25$1.261.65M
Oct 27, 2026$1.30$1.315$1.26$1.28691.46K
Oct 26, 2026$1.30$1.30$1.28$1.30392.38K
Oct 23, 2026$1.30$1.32$1.265$1.28546.63K
Oct 22, 2026$1.29$1.325$1.29$1.31501.52K
Oct 21, 2026$1.24$1.31$1.234$1.291.06M
Oct 20, 2026$1.32$1.35$1.21$1.231.29M
Oct 19, 2026$1.25$1.36$1.225$1.321.16M

Latest CDXS news

The latest Smart Investors Daily articles mentioning CDXS.

CDXS research

Overview

Company profile and research snapshot.

Company profile

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$11.00
Implied upside
—
Analysts
13
CDXS recent ratings
DateFirmRatingTarget
Aug 17, 2026Piper SandlerOverweight—
Nov 22, 2024Cantor FitzgeraldOverweight—
Nov 15, 2024Cantor FitzgeraldOverweight—
Nov 4, 2024BenchmarkHold—
Sep 20, 2024Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

Codexis Enters into $60 Million Term Loan Facility with Trinity Capital

Initial drawdown of $42.5 million to refinance existing term loanREDWOOD CITY, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced it has entered into a $60 million senior secured term loan agreement with Trinity Capital Inc. (NYSE: TRIN), a leading provider of flexible capital solutions for life sciences and healthcare industries. The Company used the proceeds of

Yahoo · Nov 9, 2026

Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities

Data shared at TIDES Europe demonstrates consistent and robust platform performance while delivering high product quality at scale, alongside new platform capabilities in targeting functionality and initial results showcasing that stereochemical control relates to biological efficacyREDWOOD CITY, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, present

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.